BGB 15025
Alternative Names: BGB-15025Latest Information Update: 01 Apr 2026
At a glance
- Originator BeiGene
- Developer BeOne Medicines
- Class Antineoplastics; Small molecules
- Mechanism of Action Hematopoietic progenitor kinase 1 inhibitors
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Phase II Non-small cell lung cancer
- Phase I Solid tumours
Most Recent Events
- 12 Jun 2025 Pharmacodynamics data from a preclinical trial in Acute-myeloid-leukemia presented at the 30th Congress of the European Haematology Association (EHA-2025)
- 30 May 2025 Efficacy and adverse events data from a phase II trial in Non-small lung cancer presented at 61st Annual Meeting of the American Society of Clinical Oncology (ASCO-2025)
- 27 Dec 2024 Chemical structure information added.